SE462016B - Foerfarande foer iordningsstaellande av en lyofiliserad farmaceutisk sammansaettning med vaevnadsplasminogen-aktivator, t-pa - Google Patents

Foerfarande foer iordningsstaellande av en lyofiliserad farmaceutisk sammansaettning med vaevnadsplasminogen-aktivator, t-pa

Info

Publication number
SE462016B
SE462016B SE8602405A SE8602405A SE462016B SE 462016 B SE462016 B SE 462016B SE 8602405 A SE8602405 A SE 8602405A SE 8602405 A SE8602405 A SE 8602405A SE 462016 B SE462016 B SE 462016B
Authority
SE
Sweden
Prior art keywords
solution
aqueous solution
pharmaceutical composition
lyophilized
concentration
Prior art date
Application number
SE8602405A
Other languages
English (en)
Swedish (sv)
Other versions
SE8602405D0 (sv
SE8602405L (sv
Inventor
M D Johnston
H Berger
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858513358A external-priority patent/GB8513358D0/en
Priority claimed from GB858521705A external-priority patent/GB8521705D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of SE8602405D0 publication Critical patent/SE8602405D0/xx
Publication of SE8602405L publication Critical patent/SE8602405L/xx
Publication of SE462016B publication Critical patent/SE462016B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE8602405A 1985-05-28 1986-05-27 Foerfarande foer iordningsstaellande av en lyofiliserad farmaceutisk sammansaettning med vaevnadsplasminogen-aktivator, t-pa SE462016B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858513358A GB8513358D0 (en) 1985-05-28 1985-05-28 Formulation
GB858521705A GB8521705D0 (en) 1985-08-31 1985-08-31 Formulation

Publications (3)

Publication Number Publication Date
SE8602405D0 SE8602405D0 (sv) 1986-05-27
SE8602405L SE8602405L (sv) 1986-11-29
SE462016B true SE462016B (sv) 1990-04-30

Family

ID=26289290

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8602405A SE462016B (sv) 1985-05-28 1986-05-27 Foerfarande foer iordningsstaellande av en lyofiliserad farmaceutisk sammansaettning med vaevnadsplasminogen-aktivator, t-pa

Country Status (22)

Country Link
US (2) US4929444A (fr)
JP (1) JPH0759517B2 (fr)
AU (1) AU567236B2 (fr)
BE (1) BE904830A (fr)
CA (1) CA1300008C (fr)
CH (1) CH665356A5 (fr)
DE (1) DE3617752A1 (fr)
DK (1) DK163173C (fr)
ES (2) ES8800601A1 (fr)
FI (1) FI85335C (fr)
FR (1) FR2583984B1 (fr)
GB (1) GB2176702B (fr)
GR (1) GR861366B (fr)
HU (1) HU195733B (fr)
IL (1) IL78938A (fr)
IT (1) IT1191926B (fr)
LU (1) LU86444A1 (fr)
NL (1) NL8601355A (fr)
NO (1) NO171345C (fr)
NZ (1) NZ216307A (fr)
PT (1) PT82646B (fr)
SE (1) SE462016B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ216306A (en) * 1985-05-28 1989-10-27 Wellcome Found Pharmaceutical compositions containing tissue plasminogen activator
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
DK237187A (da) * 1986-05-12 1987-11-13 Wellcome Found Farmaceutisk anvendelse af t-pa
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
GB8619098D0 (en) * 1986-08-05 1986-09-17 Wellcome Found Combination
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
WO1992011866A1 (fr) * 1991-01-14 1992-07-23 Duke University SEQUENCE DE LAMININE UTILES COMME ACTIVATEUR DE tPA
JP3559559B2 (ja) * 1992-06-03 2004-09-02 ジェネンテク，インコーポレイテッド 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体
DE69629826T2 (de) * 1995-10-23 2004-07-01 Children's Medical Center Corp., Boston Therapeutische antiangiogenische zusammensetzungen und verfahren
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
NZ330537A (en) * 1995-12-13 2001-06-29 Childrens Medical Center Kringle 5 rerion of plasminogen as an endothelial cell proliferation inhibitor
DK0827751T3 (da) * 1996-09-06 2003-03-31 Chemo Sero Therapeut Res Inst Medicinsk præparat indeholdende vævsplasminogenaktivator og nicotinamid
EP1432437A2 (fr) * 2001-09-07 2004-06-30 Global Biotech Inc. Formulation contenant un activateur de plasminogene de type urokinase de tissu humain
US20040091465A1 (en) * 2002-06-26 2004-05-13 Zachary Yim Therapeutic antiangiogenic compositions and methods
WO2005003304A2 (fr) * 2003-06-20 2005-01-13 Illumina, Inc. Methodes et compositions utiles pour l'amplification et le genotypage du genome tout entier
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
EP1879599B1 (fr) * 2005-04-20 2013-10-16 Fred Hutchinson Cancer Research Center Procedes, compositions et articles manufactures permettant d'ameliorer la capacite de survie de cellules, de tissus, d'organes et d'organismes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998947A (en) * 1973-11-30 1976-12-21 Pierre Fabre S.A. Process for obtaining a plasminogen activator
FR2252842B1 (fr) * 1973-12-03 1977-11-04 Fabre Sa Pierre
DE3015699C2 (de) * 1979-04-26 1982-07-15 Asahi Kasei Kogyo K.K., Osaka Herstellung eines Plasminogen-Aktivators
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
CH660742A5 (de) * 1982-10-29 1987-06-15 Mitsui Toatsu Chemicals Plasminogen-aktivator, verfahren zu seiner herstellung und diesen enthaltendes thrombolytisches agens.
AU554862B2 (en) * 1982-12-14 1986-09-04 Implico B.V. Plasminogen activator isolated by affinity chromatography
NZ206699A (en) * 1982-12-30 1989-08-29 Bio Response Inc Process for the production of serum independent cell lines
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
EP0156169B1 (fr) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha Solution aqueuse d'un activateur tissulaire du plasminogène dissous à une concentration élevée et un procédé d'obtention
DE3439980A1 (de) * 1984-11-02 1986-05-07 Behringwerke Ag, 3550 Marburg Verfahren zur reinigung sowie pasteurisierung von urokinase
EP0201153A3 (fr) * 1985-02-09 1987-10-07 Beecham Group Plc Enzyme modifié et son procédé de préparation
GB8513358D0 (en) * 1985-05-28 1985-07-03 Wellcome Found Formulation
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法

Also Published As

Publication number Publication date
ES555353A0 (es) 1987-11-16
NL8601355A (nl) 1986-12-16
BE904830A (fr) 1986-11-27
DK246786D0 (da) 1986-05-27
LU86444A1 (fr) 1986-12-05
NZ216307A (en) 1989-10-27
PT82646A (en) 1986-06-01
FI85335B (fi) 1991-12-31
FI862227A (fi) 1986-11-29
NO171345B (no) 1992-11-23
IL78938A (en) 1993-02-21
IT1191926B (it) 1988-03-31
DK246786A (da) 1986-11-29
PT82646B (pt) 1989-01-30
HUT41638A (en) 1987-05-28
SE8602405D0 (sv) 1986-05-27
FR2583984B1 (fr) 1989-06-02
JPH0759517B2 (ja) 1995-06-28
IT8648065A0 (it) 1986-05-27
GB2176702A (en) 1987-01-07
HU195733B (en) 1988-07-28
AU567236B2 (en) 1987-11-12
DE3617752A1 (de) 1986-12-04
SE8602405L (sv) 1986-11-29
GB2176702B (en) 1989-07-05
FI85335C (fi) 1992-04-10
GR861366B (en) 1986-09-29
FR2583984A1 (fr) 1987-01-02
FI862227A0 (fi) 1986-05-27
NO862096L (no) 1986-12-01
ES8800601A1 (es) 1987-11-16
NO171345C (no) 1993-03-03
GB8612780D0 (en) 1986-07-02
DE3617752C2 (fr) 1988-06-30
US4968617A (en) 1990-11-06
ES8802439A1 (es) 1988-06-01
IL78938A0 (en) 1986-09-30
ES557374A0 (es) 1988-06-01
DK163173B (da) 1992-02-03
US4929444A (en) 1990-05-29
CA1300008C (fr) 1992-05-05
DK163173C (da) 1992-06-22
CH665356A5 (de) 1988-05-13
AU5796486A (en) 1986-12-04
JPH06183995A (ja) 1994-07-05

Similar Documents

Publication Publication Date Title
SE462016B (sv) Foerfarande foer iordningsstaellande av en lyofiliserad farmaceutisk sammansaettning med vaevnadsplasminogen-aktivator, t-pa
SE462893B (sv) Vattenhaltig parenteral loesning av vaevnadsplasminogenaktivator och saett foer framstaellning av den
KR100705997B1 (ko) 안정화된 hgf 동결건조제제 및 그 제조방법
EA002149B1 (ru) Улучшенные способы приготовления активированного белка с
NO319174B1 (no) Lyofilisert tilberedningsform av en transglutaminase samt anvendelse av denne
JP2916947B2 (ja) Ｃｐｂ―ｉの安定化方法及び製剤組成物
CA2475738A1 (fr) Formulations de proteines c activees
JPH0369332B2 (fr)
JP2916948B2 (ja) Ｃｐｂ―ｉの安定化方法及びこの製剤組成物
CA1338551C (fr) Medicament a base de tpa pour troubles thrombotiques
AU625914B2 (en) Thrombus agent control
KR20150069962A (ko) 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8602405-6

Effective date: 19941210

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8602405-6

Format of ref document f/p: F